Clinical Trials

Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in patients with Multiple Myeloma


Study ID
Cartesian Therapeutics-241-59-88

NCT Number
NCT03448978 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0516

Principle Investigator
Dr. David Vesole

Phase
I

Sponsor
Cartesian Therapeutics


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now